Clinical Trial Protocol
Iranian Registry of Clinical Trials

13 Nov 2026

effect of Hesperidin,Artemisinin- Artemisia annua, Noscapine, N-acetylcysteine, Resveratrol supplements and high dose of vitamin C on treatment, clinical symptoms of non-hospitalization and hospitalization patients with symptomatic COVID-19

Protocol summary

Study aim
Determination of the effect of Hesperidin,Artemisinin-Artemisia annua, Noscapine, N-acetylcysteine, Resveratrol supplements and high dose of vitamin C on treatment, clinical symptoms of non-hospitalization and hospitalization patients with symptomatic COVID-19

Design
Clinical trial with control group, with parallel groups, double-blind, randomized, phase 3 per 100 patients. Block randomization method was used .

Settings and conduct
The study will be performed at Imam Reza Hospital in Sirjan. 25 patients in all four groups with symptomatic Covid-19 virus will be identified with the same .Hesperidin,Artemisinin- Artemisia annua, Noscapine, N-acetylcysteine, Resveratrol supplements and high dose of vitamin C With specific doses will be received in the intervention groups and the control groups will receive the National Protocol of the Ministry of Health. In this study, the work will be a double-blind clinical trial (Participant, Evaluator, Data analyst, Data safety and Monitoring committee)

Participants/Inclusion and exclusion criteria
Inclusion criteria: COVID-19 virus infection,Clinical symptoms, Lymphocytes less than 15%, Lung involvement in CT scan, Oxygen level less than 93%, Unstable vital signs Exclusion criteria: Allergy to oral supplements and high doses of vitamin C, Pregnant and lactating women, Patients with seizures Dialysis patients

Intervention groups
Intervention group: non-hospitalization patients received Supplements and high dose of vitamin C Intervention group: hospitalization patients received Supplements and high dose of vitamin C Control group: non-hospitalization patients received Protocol of the Ministry of Health Control group: hospitalization patients received Protocol of the Ministry of Health

Main outcome variables
LDH, CBC diff, Na / K / Ca, CRP, ESR1, Weakness and nausea, Respiratory quality

General information

Reason for update

Acronym

IRCT registration information
IRCT registration number: **IRCT20181030041504N1**
Registration date: **2020-11-08, 1399/08/18**
Registration timing: **retrospective**

Last update: **2020-11-08, 1399/08/18**
Update count: **0**

Registration date
2020-11-08, 1399/08/18

Registrant information

Name
masoomeh mohamadpour

Name of organization / entity

Country
Iran (Islamic Republic of)

Phone
+98 21 8860 7357

Email address
mohamadpour.m@iums.ac.ir

Recruitment status
Recruitment complete

Funding source

Expected recruitment start date
2020-10-07, 1399/07/16

Expected recruitment end date

2020-11-05, 1399/08/15

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

effect of Hesperidin,Artemisinin- Artemisia annua, Noscapine, N-acetylcysteine, Resveratrol supplements and high dose of vitamin C on treatment, clinical symptoms of non-hospitalization and hospitalization patients with symptomatic COVID-19

Public title

Evaluation of the combined effect of Hesperidin,Artemisinin- Artemisia annua, Noscapine, N-acetylcysteine, Resveratrol supplements and high dose of vitamin C on treatment, clinical symptoms of non-hospitalization and hospitalization patients with symptomatic COVID-19

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

COVID-19 virus infection by RT-PCR in non-hospitalization and hospitalization patients G6PD sufficient in non-hospitalization and hospitalization patients Lack of clinical response to routine outpatient treatment in non-hospitalization and hospitalization patients Clinical symptoms (fever, cough, myalgia, shortness of breath, digestive problems) in non-hospitalization and hospitalization patients Age over 12 years in non-hospitalization and hospitalization patients Patient satisfaction in non-hospitalization and hospitalization patients Lymphocytes less than 15%, respiratory distress, lung involvement on CT scan, oxygen level less than 93%, unstable vital signs, severe gastrointestinal symptoms and oral intolerance, underlying disease Except for exclusion cases hospitalization patients

Exclusion criteria:

Allergy to oral supplements and high doses of vitamin C Reluctance to continue participating in the trial for any reason Patients admitted to the intensive care unit (ICU) (patients who have been admitted to the ICU since admission) Pregnant and lactating lady Patients with seizures Dialysis patients

Age

From **12 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Outcome assessor
- Data analyser
- Data and Safety Monitoring Board

Sample size

Target sample size: **100**

Randomization (investigator's opinion)

Randomized

Randomization description

For this purpose, we will use the quadruple block method (Block Randomization). Random allocation software will be used for this purpose. We prepare two sheets of paper. On a sheet we write the letter I meaning "Intervention" and on a sheet the letter S means "Standard treatment". Mix the sheets together and place them in the desk drawer. With the referral of each eligible patient, one of the leaflets will be randomly taken out and based on this extracted leaflet will be assigned to one of the two intervention groups. It should be noted that the pulled out sheets will not be returned to the drawer until all four sheets have been pulled out. After accidentally pulling out all four sheets, all the sheets are returned to the drawer and the above procedure will be continued for the next four patients until the desired sample size is reached.

Blinding (investigator's opinion)

Double blinded

Blinding description

Participant, Evaluator, Data analyst, Data safety and Monitoring committee

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

sirjan faculty of medical science

Street address

sirjan - Seyyed Jamaledin Asad Abadi Blvd - Parks of Traffic - Sirjan University of Medical Sciences

City

sirjan

Province

Kerman

Postal code

7816916338

Approval date

2020-10-07, 1399/07/16

Ethics committee reference number

IR.SIRUMS.REC.1399.033

Health conditions studied

1

Description of health condition studied

covid-19

ICD-10 code

RA01.0

ICD-10 code description

Severe Acute Respiratory Syndrome coronavirus

Primary outcomes

1

Description

LDH

Timepoint

Before the intervention and ten days after the intervention

Method of measurement

Blood Test

2

Description

CBC diff

Timepoint

Before the intervention and ten days after the intervention

Method of measurement

Blood Test

3

Description

Na/K/Ca

Timepoint

Before the intervention and ten days after the intervention

Method of measurement

Blood Test

4

Description

CRP

Timepoint

Before the intervention and ten days after the intervention

Method of measurement

Blood Test

5

Description

ESR1

Timepoint

Before the intervention and ten days after the intervention

Method of measurement

Blood Test

6

Description

Weakness and nausea

Timepoint

Before the intervention and ten days after the intervention

Method of measurement

Check List

7

Description

Lung involvement

Timepoint

Before the intervention and ten days after the intervention

Method of measurement

CT-Scan

Secondary outcomes

1

Description

Determination of the effect of Hesperidin,Artemisinin-Artemisia annua, Noscapine, N-acetylcysteine, Resveratrol supplements and high dose of vitamin C on on oxygen

Timepoint

10 day

Method of measurement

Pulse Oximeter

2

Description

General condition of people and vitality after treatment

Timepoint

10 day

Method of measurement

Examination and history

Intervention groups

1

Description

Intervention group: non-hospitalization patients with symptomatic COVID-19 received 1. Artemisia annua - Artemisinin (Manufactured by Longlifenutri)150 mg every 24 hours 2. Dose of 1 g of vitamin C (Manufactured by Daroupakhsh) intravenous vitamin (2 ampoules of 500 mg in 250 cc of sodium chloride serum for 30 minutes) every 24 hours 3. Dose of 5 cc of noscapine (Manufactured by Faran Shimi) each Eight hours 4. 500 mg dose of hesperidin (Manufactured by Swanson) every 24 hours 5. Resveratrol 500 mg (Manufactured by A Squard) every 24 hours 6. NAC 600 mg (Manufactured by Osvah) every 12 hours . The duration of treatment is estimated at ten days. Supplements are taken orally and vitamin C is given to patients as an injection

Category

Treatment - Drugs

2

Description

Control group: non-hospitalization patients with

symptomatic COVID-19 Protocol of the Ministry of Health

Category

Treatment - Drugs

3

Description

Intervention group: hospitalization patients with symptomatic COVID-19 received 1. Artemisia annua - Artemisinin (Manufactured by Longlifenutri)150 mg every 12hours 2. Dose of 1 g of vitamin C (Manufactured by Daroupakhsh) intravenous vitamin (2 ampoules of 500 mg in 250 cc of sodium chloride serum for 30 minutes) every 12 hours 3. Dose of 5 cc of noscapine (Manufactured by Faran Shimi) each Eight hours 4. 500 mg dose of hesperidin (Manufactured by Swanson) every 24 hours 5. Resveratrol 500 mg (Manufactured by A Squard) every 24 hours 6. NAC 600 mg (Manufactured by Osvah) every 12 hours . The duration of treatment is estimated at ten days.Supplements are taken orally and vitamin C is given to patients as an injection

Category

Treatment - Drugs

4

Description

Control group: hospitalization patients with symptomatic COVID-19 Protocol of the Ministry of Health

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

بیمارستان امام رضا

Full name of responsible person

دکتر علی امجدی

Street address

خیابان هجرت - بیمارستان امام رضا

City

سیرجان

Province

Kerman

Postal code

7816916338

Phone

+98 34 4152 4452

Email

Aamjadi50@yahoo.com

Web page address

http://emamrezahp.sirums.ac.ir/

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Sirjan Faculty of Medical Science

Full name of responsible person

Dr.Mahood reza Masoudi

Street address

Seyyed Jamaledin Asad Abadi Blvd - Parks of Traffic

City

Sirjan

Province

Kerman

Postal code

7816916338

Phone

+98 34 4227 3696

Email

ssm@sirums.ac.ir

Web page address

http://www.sirums.ac.ir/index.php?option=com_content&view=featured&Itemid=102&lang=en

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Sirjan Faculty of Medical Science

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Sirjan Faculty of Medical Science

Full name of responsible person

Dr.Ali,Amjadi

Position

Non-faculty specialist physician

Latest degree

Specialist

Other areas of specialty/work

Infectious diseases

Street address

Seyyed Jamaledin Asad Abadi Blvd - Parks of Traffic

City

Sirjan

Province

Kerman

Postal code

7816916338

Phone

+98 34 4234 0640

Email

Aamjadi50@yahoo.com

Person responsible for scientific inquiries

Contact

Name of organization / entity
Rayan Research Company
Full name of responsible person
Dr. Masoomeh Mohamadpour
Position
Managing Director
Latest degree
Ph.D.
Other areas of specialty/work
Anatomical-cellular and molecular sciences
Street address
No 16, Gisha Ave
City
tehran
Province
Tehran
Postal code
1448643643
Phone
+98 21 8827 5219
Email
m.mohamadpour2817@yahoo.com

Person responsible for updating data

Contact

Name of organization / entity
Rayan Research Company
Full name of responsible person
Dr. Masoomeh Mohamadpour
Position
Managing Director
Latest degree
Ph.D.
Other areas of specialty/work
Anatomical-cellular and molecular sciences
Street address
No. 16, Gisha Ave
City
tehran
Province
Tehran
Postal code
1448643643
Phone
+98 21 8827 5219
Email
m.mohamadpour2817@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Yes - There is a plan to make this available
Data Dictionary
No - There is not a plan to make this available
Title and more details about the data/document
Main outcome data, statistical analysis, final report, informed consent form
When the data will become available and for how long
6 months after publish the results
To whom data/document is available
Academic researchers
Under which criteria data/document could be used
Master of Medical Sciences PhD in Medical Sciences specialist Contribute to the advancement of science
From where data/document is obtainable
Email m.mohamadpour2817@yahoo.com Contact number: 09120031782 Dr. Masoomeh Mohamadpour - Tehran
What processes are involved for a request to access data/document
48-72 hours after sending the email request
Comments